Clinical trials: Delayed Bleeding
Aneurysmal Subarachnoid Hemorrhage
Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)
The purpose of the study is to measure how effective and safe three different doses of the drug clazosentan are in preventing vasospasm after subarachnoid hemorrhage.
- Trial name
- CONSCIOUS-1 (NCT00111085)
- Testing
- Clazosentan 1 mg/h, Clazosentan 5 mg/h, Clazosentan 15 mg/h
- Where
- 16 sites in United States, Canada
- Volunteers
- 413 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Aneurysmal Subarachnoid Hemorrhage, Cerebral Vasospasm
Safety Study of Carotid Body Neurostimulation to Treat Cerebral Vasospasm
The purpose of this study is to evaluate the safety and performance of the Delta system in the treatment of cerebral vasospasm post aneurysmal subarachnoid hemorrhage (aSAH) patients.
- Trial name
- NCT02129413
- Testing
- Delta system
- Where
- 7 sites in Czechia, Germany and 1 more
- Volunteers
- 23 people
- Sponsor
- Samson NeuroSciences
Cerebral Ischemia
Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) Following Subarachnoid Hemorrhage (SAH)
Safety and effect of SANGUINATE on patients DCI following SAH.
- Trial name
- NCT02323685
- Testing
- SANGUINATE™
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Prolong Pharmaceuticals
Aneurysmal Subarachnoid Hemorrhage
Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain
This study will evaluate if clazosentan (on top of normal routine medical care) can reduce the risk of developing complications related to cerebral vasospasm and permanent brain damage as compared to normal routine medical care…
- Trial name
- REACT (NCT03585270)
- Testing
- Clazosentan
- Where
- 80 sites in United States, Austria and 13 more
- Volunteers
- 409 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.